CNS Relapses in Childhood ALL: Treatment Regimens With BFM Backbone
| Study . | Patients . | CRT . | MTX(g) . | eTIT . | Reported Isolated CNS Relapse (%) . | Median Follow-Up (yrs) . | Reference . | |
|---|---|---|---|---|---|---|---|---|
| N . | %7-150 . | |||||||
| DCLSG-ALL-7 | 218 | − | 5 | − | 5.5 | 5 | 35 | |
| SRG − protocol II | 44 | 20 | − | 5 | − | 11.4 | ||
| SRG + protocol II | 30 | 14 | − | 5 | − | 0 | ||
| RG | 127 | 58 | − | 5 | − | 5.5 | ||
| EG | 17 | 8 | − | 5 | − | 0 | ||
| BFM-ALL-86 | 998 | 1.8 | 5 | 1 | ||||
| SRG − protocol II | 110 | 11 | − | 5 | − | 1.8 | ||
| SRG + protocol II | 175 | 18 | − | 5 | − | 1.1 | ||
| RG | 610 | 61 | + | 5 | − | 1.1 | ||
| EG | 103 | 10 | + | 5 | − | 6.8 | ||
| GATLA | 3 | 22 | ||||||
| MRG | 490 | − | − | 2 | − | 3.1 | ||
| INS-89 | ||||||||
| SRG | 39 | 17 | − | 5 | + | 0.0 | 3.5 | 24 |
| RG | 155 | 69 | − | 5 | + | 2.3 | ||
| AIEOP ALL-88 | 6 | 23 | ||||||
| SR | 79 | 19 | − | 5 | − | 6.3 | ||
| IR | 119 | 30 | − | 5 | + | 0.8 | ||
| HR | 198 | 50 | + | 5 | − | 7.1 | ||
| CCG 1882 | 317 | − | + | − | − | 2.3 | 5 | 26 |
| HR | 319 | − | − | − | + | 3.6 | 5 | |
| Study . | Patients . | CRT . | MTX(g) . | eTIT . | Reported Isolated CNS Relapse (%) . | Median Follow-Up (yrs) . | Reference . | |
|---|---|---|---|---|---|---|---|---|
| N . | %7-150 . | |||||||
| DCLSG-ALL-7 | 218 | − | 5 | − | 5.5 | 5 | 35 | |
| SRG − protocol II | 44 | 20 | − | 5 | − | 11.4 | ||
| SRG + protocol II | 30 | 14 | − | 5 | − | 0 | ||
| RG | 127 | 58 | − | 5 | − | 5.5 | ||
| EG | 17 | 8 | − | 5 | − | 0 | ||
| BFM-ALL-86 | 998 | 1.8 | 5 | 1 | ||||
| SRG − protocol II | 110 | 11 | − | 5 | − | 1.8 | ||
| SRG + protocol II | 175 | 18 | − | 5 | − | 1.1 | ||
| RG | 610 | 61 | + | 5 | − | 1.1 | ||
| EG | 103 | 10 | + | 5 | − | 6.8 | ||
| GATLA | 3 | 22 | ||||||
| MRG | 490 | − | − | 2 | − | 3.1 | ||
| INS-89 | ||||||||
| SRG | 39 | 17 | − | 5 | + | 0.0 | 3.5 | 24 |
| RG | 155 | 69 | − | 5 | + | 2.3 | ||
| AIEOP ALL-88 | 6 | 23 | ||||||
| SR | 79 | 19 | − | 5 | − | 6.3 | ||
| IR | 119 | 30 | − | 5 | + | 0.8 | ||
| HR | 198 | 50 | + | 5 | − | 7.1 | ||
| CCG 1882 | 317 | − | + | − | − | 2.3 | 5 | 26 |
| HR | 319 | − | − | − | + | 3.6 | 5 | |
Abbreviations: MTX (g), high-dose intravenous methotrexate (grams per square meter of body surface per dose); CRT, cranial radiotherapy; eTIT, extended triple intrathecal therapy (diadreson-F, methotrexate, cytosine-arabinoside).
Percentage of total ALL population.